首页> Clinical cancer research : an official journal of the American Association for Cancer Research> Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.

导出原文传递

翻译打印收藏纠错

第一作者： Johann S,de Bono

第一单位： The Royal Marsden/Institute of Cancer Research, London, United Kingdom. Johann.DeBono@icr.ac.uk.

作者： Johann S,de Bono ^[1] ; Ugo,De Giorgi ^[2] ; Daniel Nava,Rodrigues ^[3] ; Christophe,Massard ^[4] ; Sergio,Bracarda ^[5] ; Albert,Font ^[6] ; Jose Angel,Arranz Arija ^[7] ; Kent C,Shih ^[8] ; George Daniel,Radavoi ^[9] ; Na,Xu ^[10] ; Wai Y,Chan ^[10] ; Han,Ma ^[10] ; Steven,Gendreau ^[10] ; Ruth,Riisnaes ^[3] ; Premal H,Patel ^[10] ; Daniel J,Maslyar ^[10] ; Viorel,Jinga ^[9]

作者单位： The Royal Marsden/Institute of Cancer Research, London, United Kingdom. Johann.DeBono@icr.ac.uk. ^[1] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, (IRST) IRCCS, Meldola, Italy. ^[2] The Royal Marsden/Institute of Cancer Research, London, United Kingdom. ^[3] Institut Gustave Roussy, Villejuif, France. ^[4] Medical Oncology, Ospedale San Donato, Azienda USL Toscana Sud-Est, Istituto Toscano Tumori, Arezzo, Italy. ^[5] Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain. ^[6] Hospital General Universitario Gregorio Marañón, Madrid, Spain. ^[7] Tennessee Oncology, Nashville, Tennessee. ^[8] Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ^[9] Genentech, Inc., South San Francisco, California. ^[10]